ResearchPUBMED4 days ago
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study.
Researchers in Switzerland studied how many adults with inherited metabolic diseases (rare conditions where the body cannot break down certain substances properly) were able to get orphan drugs (special medicines made for rare diseases). They looked at records from 2017 to 2022 to understand which patients received these medicines, how long it took to get them approved and paid for, and what rules made it easier or harder to access them.
WHY IT MATTERSIf you have an inherited metabolic disease in Switzerland or Europe, this study shows real-world timelines for how long it typically takes to get orphan drug approval and reimbursement—information that can help you advocate for faster access with your doctor and insurance company.
ℹ Good to know